RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:110

Bardet-Biedl syndrome

medium confidenceDisorder

Also known as: BBS

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

6,209

96.7th percentile

Trials

8

Interventional, condition-specific

Researchers

1,081

Distinct authors in sample

Gene link

SCLT1

Limited

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare genetic multisystem disorder characterized by the variable association of retinal , obesity, polydactyly, genitourinary and kidney anomalies, learning disability and hypogonadism, with a wide spectrum of other minor manifestations.

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Limited — SCLT1

  2. LiteraturePresent

    6,209 matched papers (3,547 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    8 matched on ClinicalTrials.gov (3 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Possibly — only limited evidence so far for SCLT1.

GenCC classification: Limited.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

6,209

6,209 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

6,209 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

3,547 in the last 10 years · medium confidence · 96.7th percentile (publications denominator)

Phrase hits: 6,209 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,081

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Pomeroy J6 papers · 2026

    Marshfield Clinic Research Institute, Marshfield, WI, USA.

    Papers in Europe PMC
  2. 02
    Cetiner M5 papers · 2026

    Department of Paediatrics II, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

    Papers in Europe PMC
  3. 03
    Dollfus H5 papers · 2026

    Laboratoire de Génétique Médicale, UMRS_1112, Institut de Génétique Médicale d'Alsace, INSERM-Université de Strasbourg, Strasbourg, France.

    Papers in Europe PMC
  4. 04
    Haqq AM5 papers · 2026

    Division of Pediatric Endocrinology, University of Alberta, Edmonton, Alberta, Canada.

    Papers in Europe PMC
  5. 05
    Kumar S5 papers · 2026

    Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA.

    Papers in Europe PMC
  6. 06
    Dauleh H4 papers · 2026

    Division of Endocrinology, Department of Pediatric Medicine, Sidra Medicine, Doha, Qatar.

    Papers in Europe PMC
  7. 07
    Hussain K4 papers · 2026

    Division of Endocrinology, Department of Pediatric Medicine, Sidra Medicine, Doha, Qatar.

    Papers in Europe PMC
  8. 08
    Richards J4 papers · 2026

    Department of Internal Medicine, University of Oklahoma at Tulsa, Tulsa, Oklahoma, USA.

    Papers in Europe PMC
  9. 09
    Sigurdardottir S4 papers · 2026

    Centre for Rare Disorders, Oslo University Hospital, Oslo, Norway.

    Papers in Europe PMC
  10. 10
    von der Lippe C4 papers · 2026

    Department of Medical Genetics, Telemark Hospital Trust, Skien, Norway.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

8

interventional trials for this specific condition

8 interventional trials matched this specific condition name; 3 currently recruiting in our sample.

Data as of 27 July 2026

8 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 90.6th percentile).

medium confidence · 90.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

8 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

10 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Bardet-Biedl syndrome"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Bardet-Biedl syndrome" OR "SCLT1"

Recall-expansion terms: SCLT1

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 8 interventional · 10 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: BBS

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T12:27:32.285Z